scispace - formally typeset
Journal ArticleDOI

What is the true solubility advantage for amorphous pharmaceuticals

Bruno C. Hancock, +1 more
- 01 Apr 2000 - 
- Vol. 17, Iss: 4, pp 397-404
Reads0
Chats0
TLDR
Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations.
Abstract
Purpose To evaluate the magnitude of the solubility advantage foramorphous pharmaceutical materials when compared to their crystallinecounterpartsMethods The thermal properties of several drugs in their amorphousand crystalline states were determined using differential scanningcalorimetry From these properties the solubility advantage for theamorphous form was predicted as a function of temperature using a simplethermodynamic analysis These predictions were compared to theresults of experimental measurements of the aqueous solubilities of theamorphous and crystalline forms of the drugs at several temperaturesResults By treating each amorphous drug as either an equilibriumsupercooled liquid or a pseudo-equilibrium glass, the solubilityadvantage compared to the most stable crystalline form was predicted to bebetween 10 and 1600 fold The measured solubility advantage wasusually considerably less than this, and for one compound studied indetail its temperature dependence was also less than predicted It wascalculated that even for partially amorphous materials the apparentsolubility enhancement (theoretical or measured) is likely to influencein-vitro and in-vivo dissolution behaviorConclusions Amorphous pharmaceuticals are markedly more solublethan their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations This appears to be the result of difficulties indetermining the solubility of amorphous materials under trueequilibrium conditions Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage foramorphous pharmaceuticals, which directly reflects the driving forcefor their initial dissolution

read more

Content maybe subject to copyright    Report

Citations
More filters
Patent

Pseudopolymorphic forms of a hiv protease inhibitor

TL;DR: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed as mentioned in this paper.
Journal ArticleDOI

Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.

TL;DR: The results showed that the co‐amorphous formulation did not recrystallize during the coating process or during storage at both storage conditions for up to three months, which confirmed the high physical stability of this co-amorphous system.
Journal ArticleDOI

Effect of copolymer composition on particle morphology and release behavior in vitro using progesterone

TL;DR: In this article, the effects of polymer: drug ratio and copolymer composition on particle properties and in vitro drug-release profile were investigated, and the obtained results indicated that the prepared microparticles were ideal carriers for oral administration of progesterone offering great potential to improve the dissolution rate of drugs that suffer from low aqueous solubility.
Journal ArticleDOI

Large-Scale Preparation of Amorphous Cefixime Nanoparticles by Antisolvent Precipitation in a High-Gravity Rotating Packed Bed

TL;DR: In this paper, amorphous Cefixime nanoparticles were prepared via high-gravity antisolvent precipitation (HGAP) without the aid of any pharmaceutical additives in a rotating packed bed (RPB).
References
More filters
Journal ArticleDOI

Characteristics and Significance of the Amorphous State in Pharmaceutical Systems

TL;DR: The amorphous state is critical in determining the solid-state physical and chemical properties of many pharmaceutical dosage forms and some of the most common methods that can be used to measure them are described.
Book

Polymorphism in Pharmaceutical Solids

TL;DR: Brittain et al. as mentioned in this paper applied the phase rule to the characterisation of polymorphic and solvatomorphic systems, and proposed a computational method to predict polymorphism.
Journal ArticleDOI

Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations

TL;DR: It is hoped that this review will lead to a more direct approach to the characterization of pharmaceuticalsolids and ultimately to faster approval of regulatory documents containing information on pharmaceutical solids.
Journal ArticleDOI

Crystallization of Indomethacin from the Amorphous State below and above Its Glass Transition Temperature

TL;DR: It was shown that in both samples significant crystallization to the most stable polymorphic form occurred over several days when stored below Tg, and in some cases this process was preceded by the relaxation of one amorphous form to the other.
Journal ArticleDOI

Characterization of the time scales of molecular motion in pharmaceutically important glasses

TL;DR: In this paper, the authors characterized the molecular mobility of selected amorphous systems (i.e., indomethacin, sorbitol, sucrose, and trehalose) below Tg using a combined experimental and theoretical approach.
Related Papers (5)